{
    "Trade/Device Name(s)": [
        "DCA Vantage",
        "DCA Vantage\u2122",
        "DCA Vantage\u2122, Model 5075"
    ],
    "Submitter Information": "Siemens Medical Solutions Diagnostics",
    "510(k) Number": "K071466",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951361",
        "K963142"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JIR",
        "CGX"
    ],
    "Summary Letter Date": "September 5, 2007",
    "Summary Letter Received Date": "September 6, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.1645",
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Glycosylated Hemoglobin Assay",
        "Urinary Protein or Albumin Test System",
        "Creatinine Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology",
        "misc"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Albumin",
        "Creatinine",
        "Albumin/Creatinine ratio"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DCA Vantage"
    ],
    "Method(s)/Technology(ies)": [
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for DCA Vantage benchtop analyzer for quantitative measurement of hemoglobin A1c in blood and albumin, creatinine, and albumin/creatinine ratio in urine.",
    "Indications for Use Summary": "Quantitatively measures percent Hemoglobin A1c in blood, low concentrations of albumin (microalbuminuria) and creatinine in urine, and albumin/creatinine ratio in urine; used for monitoring glycemic control in diabetes, screening and monitoring microalbuminuria, and early detection of kidney diseases in laboratory settings.",
    "fda_folder": "Hematology"
}